| Literature DB >> 24777450 |
Rumiko Matsuoka1,2, Kumarasamy Thangaraj3, Bruce D Gelb4,5,6, Perundurai S Dhandapany4,5,6, Md Abdur Razzaque7, Uthiralingam Muthusami8, Sreejith Kunnoth8, Jonathan J Edwards6, Sonia Mulero-Navarro6, Ilan Riess6, Sherly Pardo9, Jipo Sheng10, Deepa Selvi Rani3, Bindhu Rani11, Periyasamy Govindaraj12, Elisabetta Flex13, Tomohiro Yokota1, Michiko Furutani1,2, Tsutomu Nishizawa1, Toshio Nakanishi1,2, Jeffrey Robbins7, Giuseppe Limongelli14, Roger J Hajjar10, Djamel Lebeche10, Ajay Bahl11, Madhu Khullar11, Andiappan Rathinavel15, Kirsten C Sadler16, Marco Tartaglia13.
Abstract
Dilated cardiomyopathy (DCM) is a highly heterogeneous trait with sarcomeric gene mutations predominating. The cause of a substantial percentage of DCMs remains unknown, and no gene-specific therapy is available. On the basis of resequencing of 513 DCM cases and 1,150 matched controls from various cohorts of distinct ancestry, we discovered rare, functional RAF1 mutations in 3 of the cohorts (South Indian, North Indian and Japanese). The prevalence of RAF1 mutations was ~9% in childhood-onset DCM cases in these three cohorts. Biochemical studies showed that DCM-associated RAF1 mutants had altered kinase activity, resulting in largely unaltered ERK activation but in AKT that was hyperactivated in a BRAF-dependent manner. Constitutive expression of these mutants in zebrafish embryos resulted in a heart failure phenotype with AKT hyperactivation that was rescued by treatment with rapamycin. These findings provide new mechanistic insights and potential therapeutic targets for RAF1-associated DCM and further expand the clinical spectrum of RAF1-related human disorders.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24777450 PMCID: PMC4049514 DOI: 10.1038/ng.2963
Source DB: PubMed Journal: Nat Genet ISSN: 1061-4036 Impact factor: 38.330